Code No. | D373-3 | |
Anti-MELK (Human) mAb | ||
Size | 100 µL (1 mg/mL) | |
Availability (in Japan) | 10 or more
(In Japan at 17:33, Apr 26, 2024 in JST) |
|
Clonality | Monoclonal | |
Clone | 11-28 | |
Isotype (Immunized Animal) |
Mouse IgG1 κ | |
Applications | WB 1 µg/mL IH 1-5 µg/mL (Heat treatment is necessary for paraffin-embedded sections.) |
|
Immunogen (Antigen) |
Recombinant protein, corresponding to amino acids 264-601 of human MELK | |
Reactivity [Gene ID] | Human[9833] |
|
Storage buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 | |
Storage temp. | -20°C | |
Conjugate | Unlabeled | |
Manufacturer | MBL | |
Alternative names | maternal embryonic leucine zipper kinase, hPK38, HPK38, pEg3 kinase | |
Background | MELK is a member of the AMPK serine/threonine kinase family. It is involved in mammalian embryonic development. Overexpression of MELK protein is also reported in various types of human cancer. MELK plays critical roles not only in cancer cell growth but also in formation or maintenance of cancer stem cells that have the ability to self-renew and differentiate. Emerging evidence indicates that cancer stem cells are resistant to chemotherapy and radiation therapy and are associated with cancer relapse. For these reasons, MELK is considered a promising drug target molecule for cancer treatment. | |
Product category | Research area:Stem cell research Cancer | |
Data | ||
Citations | Immunohistochemistry
|
|
References |
|